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Growth of normal and neoplastic prostate is mediated
by the androgen receptor (AR), a ligand-dependent tran-
scription factor activated by high affinity androgen
binding. The AR is highly expressed in recurrent pros-
tate cancer cells that proliferate despite reduced circu-
lating androgen. In this report, we show that epidermal
growth factor (EGF) increases androgen-dependent AR
transactivation in the recurrent prostate cancer cell
line CWR-R1 through a mechanism that involves a post-
transcriptional increase in the p160 coactivator tran-
scriptional intermediary factor 2/glucocorticoid recep-
tor interacting protein 1 (TIF2/GRIP1). Site-specific
mutagenesis and selective MAPK inhibitors linked the
EGF-induced increase in AR transactivation to phos-
phorylation of TIF2/GRIP1. EGF signaling increased the
coimmunoprecipitation of TIF2 and AR. AR transactiva-
tion and its stimulation by EGF were reduced by small
interfering RNA inhibition of TIF2/GRIP1 expression.
The data indicate that EGF signaling through MAPK
increases TIF2/GRIP1 coactivation of AR transactiva-
tion in recurrent prostate cancer.
Prostate cancer is a common disease in men that initiates in
an environment of abundant circulating androgen. Prolifera-
tion of androgen-dependent prostate cancer cells is mediated by
the androgen receptor (AR),1 a ligand-dependent transcription
factor that is activated by binding testosterone or dihydrotes-
tosterone (DHT) (1–4). Androgen-induced cell proliferation is
associated with the expression of an array of androgen-regu-
lated genes (5, 6). Most prostate cancers regress in response to
androgen deprivation therapy or anti-androgen treatment, re-
flecting their dependence on androgens for growth. Androgen
deprivation results initially in reduced AR levels and reduced
expression of androgen-regulated genes (7). Nevertheless, pros-
tate cancers recur after a period of remission (8, 9). It has been
suggested that prostate cancer recurrence occurs under selec-
tive pressure of androgen withdrawal or anti-androgen treat-
ment and results from the clonal expansion of a subpopulation
of cells that is independent of androgen for growth (10). The
recurrence of prostate cancer after androgen deprivation is a
major clinical challenge for improving disease outcome.
An abundance of evidence suggests that the AR is critical to
recurrent prostate cancer growth despite reduced circulating
androgen levels. AR is expressed in most recurrent prostate
cancers (11) and is implicated in cancer growth by a cadre of
androgen-regulated genes that continue to be expressed in the
absence of testicular androgen (11–15). Recent studies show
that selective AR inactivation using a ribozyme inhibits prolif-
eration of LNCaP cells in culture (16). LNCaP prostate tumor
growth and PSA secretion were inhibited in vivo using anti-
sense oligonucleotides to inhibit AR expression (17).
To account for the functional importance of AR in recurrent
prostate cancer, a number of adaptive mechanisms have been
proposed (18). Each involves alternative pathways for in-
creased AR activation. One compelling observation is that the
AR gene is amplified in 30% of prostate cancers, and AR
levels are increased (9, 19–21). Higher AR expression would be
expected to increase the sensitivity of prostate cancer cells to
low androgen levels, as reported recently (22).
Mutation of the AR coding sequence is another mechanism
for increased AR activation in late stage prostate cancer
growth. Unlike mutations that cause androgen insensitivity by
inactivating AR (23), most AR mutations identified in prostate
cancer retain responsiveness to DHT (24–27). Some of these
mutations broaden the ligand binding specificity, allowing ad-
ditional steroids including adrenal androgens to induce AR
transactivation (27–32). For some mutants, such as AR-T877A,
in the LNCaP prostate tumor and derived cell lines, antago-
nists such as hydroxyflutamide gain agonist activity. AR mu-
tations identified in prostate cancer include shorter than aver-
age CAG repeat lengths (33) associated with increased AR
levels (34). The overall frequency of AR mutations in early
stage disease is 5% (35), indicating that AR mutations do not
account for prostate cancer initiation in most patients. The
frequency of AR mutations increases in late stage recurrent
prostate cancer (4, 35, 36) and may reflect adaptive changes to
low androgen levels or anti-androgen treatment (37) or is in-
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dicative of the inherent genetic instability that characterizes
advanced cancer cells.
Another mechanism for recurrent prostate cancer growth is
increased expression of nuclear receptor coactivators. The p160
coactivators include steroid receptor coactivator 1 (SRC1) (38),
transcriptional intermediary factor 2 (TIF2) (39), also known as
SRC2 or the mouse homologue, glucocorticoid receptor inter-
acting protein (GRIP1) (40), and the related SRC3 variants
TRAM1, AIB1, RAC3, ACTR, and p/CIP (41). When overex-
pressed in transient transfection assays, these coactivators
increase AR transactivation in the presence of testosterone and
DHT (42, 43) or lower affinity adrenal androgens (44). Some of
the p160 coactivators have histone acetyltransferase activity
that modifies histones to increase chromatin accessibility dur-
ing gene activation (45). We found increased levels of TIF2 and
SRC1 in the majority of a randomly selected set of clinical
specimens of recurrent prostate cancer compared with coacti-
vator levels detected in benign prostate (44). Increased coacti-
vator expression is associated with estrogen receptor-mediated
gene activation in breast (46, 47) and ovarian cancer (48),
suggesting that p160 coactivator overexpression is linked to
growth stimulation in cancer cells controlled by sex steroids.
Increased kinase signaling in response to growth factors is
another adaptive change implicated in AR transactivation in
prostate cancer (49–51). Signaling pathways that trigger in-
creased cyclic AMP-dependent protein kinase A may be a mech-
anism for increased AR transactivation in recurrent prostate
cancer (52, 53). Mitogen activation of AR is reported to occur in
the absence and presence of androgen (52) and influences AR
phosphorylation (54, 55) and dephosphorylation (56). Insulin-
like growth factor-1, keratinocyte growth factor, and epidermal
growth factor (EGF) are reported to increase AR transactiva-
tion in the absence of androgen (8, 9, 57). Mitogen-activated
protein kinase (MAPK) signaling pathways and overexpression
of the receptor ErbB2 induced ligand-independent AR transac-
tivation (58). ErbB2 lacks a ligand partner but heterodimerizes
with other members of the EGF receptor family to activate
MAPK and phosphatidylinositol 3-kinase signaling pathways.
Other reports suggest that EGF-induced increases in AR trans-
activation require the presence of androgen (59, 60). Heregu-
lin- and ErbB3 were overexpressed in prostate cancer in as-
sociation with less favorable prognosis in advanced disease
(61).
In this report, we investigated the mechanisms involved in
an EGF-induced increase in AR transcriptional activity in re-
current prostate cancer cells. We present evidence that an
EGF-induced increase in TIF2/GRIP1 phosphorylation is me-
diated through the MAPK signaling pathway and increases the
functional activity of the androgen-activated AR.
EXPERIMENTAL PROCEDURES
CWR22 Tumor Propagation—Androgen-dependent and recurrent
CWR22 tumors were originally provided by Thomas G. Pretlow (Case
Western Reserve University) and were maintained as xenograft im-
plants in nude mice (13, 62). CWR22 tumors of 1 cm or less were
resected and dispersed by protease digestion. Cell suspensions (106
cells/site) were injected subcutaneously with 100 l of Matrigel (BD
Biosciences) into nu/nu athymic mice (Harlan Sprague-Dawley, Inc.,
Indianapolis, IN) that were previously implanted with 12.5 mg of sus-
tained release testosterone pellets to normalize circulating levels to 4
ng/ml testosterone (Innovative Research of America, Sarasota, FL).
For analysis of the androgen-dependent CWR22 tumor, tumors were
grown to 0.75 g over 30 days until the mice were sacrificed by
cervical dislocation, and tumors were resected. Testosterone propionate
(25 mg/kg/day) in sesame oil (Schein Pharmaceutical, Inc., Port
Washington, NY) was injected intraperitoneally, or 150 g/kg/day EGF
in sterile water (BD Biosciences) was injected subcutaneously. For
recurrent CWR22 tumors, tumor cell-Matrigel suspensions were in-
jected into castrated athymic mice and grown to 0.75 g before resec-
tion after 30 days. Tumors were frozen in liquid N2 and used to
prepare protein lysates for immunoblot analysis. Animals were main-
tained in accordance with National Institutes of Health and University
of North Carolina at Chapel Hill animal use guidelines.
Plasmids—Expression vectors were described previously for full-
length human AR pCMVhAR (63), AR NH2-terminal and DNA binding
and hinge region fragment pCMVhAR 1–660 (64, 65), the AR N/C
interaction mutant pCMVhAR-FXXAA/AXXAA in which alanine sub-
stitutions were introduced into the 23FQNLF27 and 433WHTLF437 AR
NH2-terminal sequence (66–68), and GAL-AR 624–919 coding for the
GAL4 DNA binding domain as a fusion protein with the AR ligand
binding domain (69, 70). VPTIF2.1-S736A contained TIF2 residues
624–1287 and a serine to alanine mutation and was prepared by po-
lymerase chain reaction mutagenesis, and the DNA sequence was ver-
ified. The following vectors were generously provided: prostate-specific
antigen-luciferase reporter PSA-Luc (referred to previously as PSE-
Luc) containing the 5220 PSA enhancer and promoter region with an
internal deletion of 2876 to 540 (71) from Young E. Whang (Univer-
sity of North Carolina, Chapel Hill, NC) and Lily Wu (University of
California Los Angeles), VPTIF2.1 coding for TIF2 residues 624–1287
as a fusion protein with the VP16 activation domain from Heinrich
Gronemeyer (Institute of Genetics and Molecular and Cellular Biology)
(39, 70), pSG5-GRIP1 and pSG5-GRIP1-S736A from Michael R.
Stallcup and Peter J. Kushner (University of Southern California),
mouse mammary tumor virus long terminal repeat-luciferase reporter
vector (MMTV-Luc) from Stanley M. Hollenberg and Ronald M. Evans
(Salk Institute), and the GAL4 luciferase reporter 5GAL4Luc3 from
Donald P. McDonnell (Duke University).
Transient Reporter Gene Assays—Cotransfection assays were per-
formed in the CWR-R1 cell line derived from the CWR22 recurrent
human prostate cancer xenograft (22). To study transcriptional activity
of endogenous AR, CWR-R1 cells were transfected with 0.5 g/6-cm dish
MMTV-Luc reporter vector in the absence and presence of 0.1 g of
pSG5 empty vector, pSG5-GRIP1, or pSG5-GRIP1-S736A. To study
transcriptional activity of transiently expressed wild-type pCMVhAR
and pCMVAR 1–660 or pCMVAR-FXXAA/AXXAA, AR expression vec-
tor DNA (10 ng) was transfected with 0.5 g of MMTV-Luc or 1 g of
PSA-Luc reporter vector as indicated. DNA was transfected into 75%
confluent CWR-R1 cells plated the day before at 106 cells/6-cm dish
using prostate growth medium without exogenous EGF, containing
Richter’s improved minimal essential medium (Irvine Scientific, Santa
Ana, CA) supplemented with 10 mM nicotinamide, 5 g/ml insulin, 5
g/ml transferrin, 5 ng/ml selenium, 100 units/ml penicillin, 100 g/ml
streptomycin, and 2% fetal bovine serum. The Effectene transfection
reagent (Qiagen, Valencia, CA) was used according to the manufac-
turer. 1 ml of a DNA reaction mix containing 150 l of EC buffer
(Qiagen), 4 l of enhancer, 4 l of Effectene reagent (Qiagen), and 1 ml
of 2% serum containing prostate growth medium lacking EGF was
added to cell cultures containing 3 ml/dish fresh medium with 2% fetal
calf serum without added EGF. The next day, the prostate growth
medium was replaced with phenol red-free, serum-free medium (Im-
proved MEM Zinc Option; Invitrogen) with or without the addition of
EGF or DHT as indicated, and incubations were continued for 24 h.
Cells were harvested in 0.5 ml of lysis buffer containing 25 mM Tris
phosphate, pH 7.8, 2 mM EDTA, and 1% Triton X-100 (67). Luciferase
activity was measured using an automated LumiStar Galaxy (BMG
Labtechnologies, Durham, NC) multiwell plate reader luminometer.
For two-hybrid interaction assays, CWR-R1 cells (1  106 cells/6-cm
dish) were transfected using Effectene as described above with 10 ng of
VPTIF2.1 (VP16 activation residues 411–456 fused to TIF2 residues
624–1287) or the serine to alanine mutant VPTIF2.1-S736A, 100 ng of
GAL-AR 624–919, and 0.1 g of 5GAL4Luc-3 containing five tandem
GAL-4 binding sites and the luciferase coding sequence. Cells were
treated with hormone as indicated and analyzed for luciferase activity
as described above.
Immunoblot, Immunoprecipitation, and Stability Assays—Monkey
kidney COS-1 cells were maintained in Dulbecco’s modified Eagle’s
medium containing 2 mM L-glutamine, 20 mM Hepes, pH 7.2, 10%
bovine calf serum, penicillin, and streptomycin. COS cells were plated
at 50% confluence (1.2  106 COS cells/10-cm dish) and transfected
the next day using Effectene reagent. To each plate containing 8 ml of
fresh serum-containing medium was added 1 ml of a reaction mix
prepared according to the manufacturer to contain, per plate, 2 g of
pCMVhAR, pCMVhAR 1–660, pSG5-GRIP1, or pSG5-GRIP1-S736A as
indicated, 300 l of EC buffer (Qiagen), 16 l of enhancer, 10 l of
Effectene reagent (Qiagen), and 1 ml of serum-containing medium.
After an overnight incubation in 10% serum-containing medium, the
medium was exchanged with serum-free, phenol red-free medium.
CWR-R1 cells in log phase growth were plated in prostate growth
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medium lacking EGF as described. For experiments without transfec-
tion, the CWR-R1 cell culture medium was replaced for 24 h with
serum-free medium lacking phenol red and containing 0.2% lipid-rich
bovine serum albumin (AlbuMax I; Invitrogen). Hormones and growth
factors were added as indicated, and cells were incubated for 20 h
with DHT in the absence and presence of EGF. CWR-R1 and COS cells
with or without transient DNA transfection were rinsed with phos-
phate-buffered saline and placed on ice. Cells were scraped into 1 ml of
buffered saline on ice, transferred to 1.5-ml microcentrifuge tubes, and
centrifuged at 12,000  g for 2 min. The buffer was aspirated, and 50 or
100 l of RIPA buffer with protease inhibitors was added (RIPA: 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and phosphate-
buffered saline containing the protease inhibitors 0.02 mg/ml pancreas
extract, 0.005 mg/ml Pronase, 0.0005 mg/ml thermolysin, 0.003 mg/ml
chymotrypsin, and 0.33 mg/ml papain (Roche Applied Science)). Cell
pellets were disrupted by vortexing for 15 s, and lysates were incubated
on ice for 15 min. After centrifugation for 15 min at 12,000  g,
supernatants were collected, and protein concentrations were deter-
mined using the Bio-Rad protein assay. Lysates from CWR22 tumors
were prepared as described (72). Proteins (25 or 50 g/lane as indicated)
were separated on 8% acrylamide gradient gels for TIF2/GRIP1 or 10%
acrylamide gels for AR and electroblotted after SDS-PAGE to nitrocel-
lulose membranes (NitroBind, 0.22 m; Osmonics, Inc., Westborough,
MA). Rabbit polyclonal AR NH2-terminal anti-peptide antibody AR32
(73) was used at 0.7 g/ml, anti-TIF2 mouse monoclonal (BD Bio-
sciences) at 1:1,000 dilution, and anti-phospho-p42/44 antibody (Cell
Signaling Technology, Beverly, MA) at 1:1,000 dilution. Incubations
with primary antibody were for 1 h at room temperature (AR32 and
TIF2) or overnight at 4 °C (pp42/44). Anti-rabbit and anti-mouse horse-
radish peroxidase-conjugated secondary IgG antibodies (Amersham
Biosciences) were used at 1:10,000 dilution for 1 h at room temperature.
Specific signals were detected using chemiluminescence (SuperSignal®
West Dura Extended Duration Substrate; Pierce).
For TIF2 immunoprecipitation, cells were removed and washed in
buffered saline containing 2.5 mM sodium vanadate and 10 mM sodium
fluoride. Cell lysates were prepared in 1 ml of RIPA with protease
inhibitor (Complete Mini; Roche Applied Science) and phosphatase
inhibitor mixtures 1 and 2 (Sigma). 4 mg of protein was immunopre-
cipitated using anti-TIF2 antibody following a preclear step using nor-
mal mouse IgG and Protein G-Plus-agarose (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA). GRIP-1 antibody (8 g; NeoMarkers, Inc.,
Fremont, CA) and 40 l of Protein G-Plus-agarose was added to pre-
cleared lysates, and samples were incubated overnight at 4 °C with
rocking. The agarose was pelleted at 1500 rpm for 30 s at 4 °C and
washed three times with RIPA containing protease inhibitors and phos-
phatase inhibitors 2.5 mM sodium vanadate and 10 mM sodium fluoride.
The final pellet was resuspended in 40 l of electrophoresis sample
buffer, and protein was fractionated on SDS-containing 8% acrylamide
gels (Gradipore Ltd.). Proteins were electroblotted to Immobilon-P
membrane (Millipore Corp., Bedford, MA) overnight. Membranes were
incubated with blocking solution (Zymed Laboratories Inc., South San
Francisco, CA) containing 2.5 mM sodium vanadate and 10 mM sodium
fluoride overnight at 4 °C followed by incubation overnight at 4 °C with
a mixture of anti-phosphoserine antibody clone PSR-45 (Sigma) at
1:500 dilution and anti-phosphoserine antibodies 4A3, 4A9, and 16B4
(Calbiochem), each at a dilution of 1:250. Following four 30-min washes
with 0.9% NaCl, 0.05% Tween 20, and 10 mM Tris, pH 7.5, membranes
were incubated with anti-mouse IgG (Amersham Biosciences) at a
1:10,000 dilution for 30 min at room temperature, and the signal was
detected by enhanced chemiluminescence (Supersignal; Pierce).
For AR stability assays, COS cells (1.2  106 COS cells/10-cm dish)
were transfected with 1 g of pCMVhAR or pCMVhAR 1–660 using
Effectene reagent (Qiagen) as described above. After an overnight in-
cubation in 10% serum-containing medium, cells were rinsed with
phosphate-buffered saline and incubated in methionine-free modified
Eagle’s medium (Sigma) for 30 min. Tran35S-label (100 Ci/dish)
(PerkinElmer Life Sciences) was added to the cells with or without DHT
or EGF treatment and incubated for 1.5 h. Cells were washed, fresh
culture medium with or without hormone was added, and cells were
incubated for 0, 8, and 24 h. Lysates were prepared from labeled cells
using RIPA buffer containing protease inhibitors. 35S-Labeled AR pro-
tein was immunoprecipitated using AR52 IgG (73) and Pansorbin cells
(Calbiochem) and analyzed by SDS gel electrophoresis. Autoradio-
graphic signals were quantitated by densitometric scanning using an
AlphaImager 3400 densitometer and AlphaEaseFC software (Al-
phaInnotech, San Leandro, CA).
Northern Blot Analysis—CWR-R1 cells (5  106/10-cm dish) were
plated in prostate growth medium lacking EGF. The next day, cells
were washed with phosphate-buffered saline, and the medium was
changed to phenol red-free improved MEM zinc option (Invitrogen)
containing 0.2% albumin (AlbuMax I; Invitrogen). After an overnight
incubation, cells were treated without or with 100 ng/ml EGF for 24 h
in the same medium prior to RNA isolation using TRIzol Reagent
(Invitrogen) according to the manufacturer’s instructions. RNA (15 g)
aliquots were fractionated on 1% agarose gels, transferred to nylon
membranes, and hybridized with 32P-labeled pSG5TIF2 BamHI frag-
ment containing nucleotides 629–869 and a pGEM-18S-4 (Promega)
Sp6-generated fragment for control 18 S ribosomal RNA.
RNA Interference—PCR primers to amplify TIF2/GRIP1 target re-
gions were synthesized to incorporate T7 polymerase promoters on the
sense and antisense DNA strands. PCR primer sequences were based
on the DNA sequence published by Voegel et al. (39) as follows with
flanking T7 sequence in brackets: TIF2-A nucleotides 197–216, 5-[TA-
ATACGACTCACTATAGG]CCAGGGCAGAGACAAGAAAG-3; TIF2-B
nucleotides 356–376, 5-[TAATACGACTCACTATAGG]TTGCACATTT-
GTCAGGTTTGA-3. pSG5-TIF2 was used as template for Taq DNA
polymerase (Invitrogen) to amplify target regions by polymerase chain
reaction using the following conditions: 94 °C for 1 min, 55 °C for 30 s,
72 °C for 30 s (30 cycles), and 72 °C for 10 min. PCR products were
gel-purified and used as template for in vitro transcription using T7
RNA polymerase and the Silencer siRNA mixture kit (Ambion Inc.,
Austin, TX). Following DNase and RNase A treatment for 1 h, double-
stranded RNA was purified through spin columns and digested with
RNase III according to the manufacturer to yield siRNA mixtures. The
mixtures of 12–30-bp double-stranded RNAs contain 5-PO4, 3-OH,
and 2-nucleotide 3 overhangs similar to siRNA produced in vivo. Rec-
ent studies demonstrated that siRNAs generated by RNase III cleavage
are efficient for RNA interference in mammalian cells (74, 75). CWR-R1
cells were transiently cotransfected with pCMVhAR, PSA-Luc, and 10
nM siRNA mixtures for TIF2 or with glyceraldehyde-3-phosphate dehy-
drogenase as a control, using Effectene reagent (Qiagen) as described
above. In some studies, cells were cotransfected with pSG5-TIF2 (50
ng/6-cm dish) to overcome inhibition by the siRNAs. Cells were treated
with and without DHT and EGF overnight and lysed, and luciferase
activity was measured.
RESULTS
Effect of EGF on AR Transactivation in CWR-R1 Cells—The
effect of EGF on AR transactivation was determined in the
CWR-R1 cell line derived from the CWR22 recurrent human
prostate cancer xenograft. Like the CWR22 recurrent prostate
tumor, CWR-R1 cells express AR-H874Y that retains wild-type
sensitivity to androgens but has increased responsiveness to
other steroids (31). In the absence of androgen, EGF at 10, 100,
and 500 ng/ml induced a 2.0  0.3-fold increase in transacti-
vation of MMTV-Luc that was independent of the dose of EGF
(Fig. 1A). Activation in response to EGF alone was negligible
compared with the 43  3.5-fold increase in response to 0.1 nM
DHT, and the addition of EGF and 0.1 mM DHT increased this
further by 3.3  0.6-fold. An androgen-dependent EGF-induced
increase in AR transcriptional activity of 1.8  0.2-fold was
seen also with transient expression of wild-type AR and a
PSA-Luc reporter in CWR-R1 cells, and again the increase in
activity was negligible with EGF alone in the absence of DHT
(Fig. 1B). The PSA-Luc reporter is activated only weakly by
endogenous AR in CWR-R1 cells in the presence of androgen
(data not shown).
The requirement for an activated AR for a substantial EGF
response was supported by transiently expressing the consti-
tutively active AR NH2-terminal and DNA binding domain
fragment AR 1–660 that lacks the ligand binding domain. EGF
increased AR 1–660 transactivation of MMTV-Luc and PSA-
Luc reporters by 3–4-fold in CWR-R1 cells (Fig. 1C). The data
suggest that the EGF-induced increase in AR-mediated gene
activation depends on an AR that is rendered transcriptionally
competent by androgen binding or artificially by deleting the
ligand binding domain.
Effects of EGF on AR Levels—To investigate the mechanism
whereby EGF increases AR transcriptional activity in the pres-
ence of androgen, we determined the effect of EGF on AR
EGF Increases TIF2 Levels and AR Transactivation 7121
protein levels. COS cells transiently expressing full-length
wild-type AR were treated for 24 h in the absence and presence
of 10 nM DHT with or without 100 ng/ml EGF. Cell lysates were
analyzed on immunoblots using an AR-specific antibody (Fig.
2A). Full-length AR protein levels increased 2.1-fold in the
presence of 10 nM DHT, reflecting androgen-induced AR stabi-
lization (76), and 2.9-fold in the presence of DHT and EGF (Fig.
2A, lane 4), but there was no increase in the presence of EGF
alone (lane 3). The latter result indicated that EGF did not
increase transient expression of AR from the pCMVhAR plas-
mid. EGF also increased by 1.9-fold the level of AR 1–660, a
constitutively active AR NH2-terminal and DNA binding do-
main fragment (Fig. 2A, lanes 5 and 6). In CWR-R1 cells,
endogenous AR protein levels increased 3.0-fold in the presence
of DHT, but a further increase in the presence of EGF was not
detectable, and there was no increase in the presence of EGF alone
(Fig. 2B). Endogenous AR in CWR-R1 cells was shown previously
to be relatively stable in the absence of added androgen (22).
A possible effect of EGF on AR stabilization was investigated
by determining AR degradation half-times by [35S]methionine
pulse-chase labeling at 37 °C in COS cells. The half-time of AR
degradation in the absence of DHT (t  11.3  2.7 h) increased
2-fold in the presence of DHT (t  22.7  3.8 h), but there was
no further increase in the presence of DHT and EGF (t  24.0 
3.0 h). The degradation half-time of AR 1–660, which lacks the
ligand binding domain, was 20.0  3.8 h in the absence of EGF
and 24.8  2.7 h in the presence of EGF (p  0.16). The data
FIG. 1. EGF stimulation of AR transcriptional activity in
CWR-R1 cells. CWR-R1 cells were assayed as described under “Exper-
imental Procedures” for endogenous AR transactivation using MMTV-
Luc (0.5 g/6-cm dish) (A), exogenous wild-type AR activity determined
by transfecting pCMVhAR (10 ng/dish) and PSA-Luc (1 g/dish) (B),
FIG. 2. Effect of EGF on AR protein levels in COS and CWR-R1
cells. In A, COS cells were transiently transfected as described under
“Experimental Procedures” with 2 g of pCMVhAR coding for full-
length AR (lanes 1–4) and for the AR NH2-terminal fragment pCM-
VhAR 1–660 (lanes 5 and 6). Cells were incubated in the absence and
presence of 100 ng/ml EGF with or without 10 nM DHT for 24 h as
indicated. Immunoblots are shown with 25 g of protein/lane for COS
cell lysates. In B, CWR-R1 cells were incubated with and without 100
ng/ml EGF in the absence and presence of 1 nM DHT for 24 h. Extracts
were analyzed using 50 g of protein/lane for CWR-R1 cells. Blots were
incubated with AR32, an AR NH2-terminal specific antibody. Densitom-
etry values for specific bands are included below the lanes and are
representative of more than three independent experiments.
and constitutively active AR deletion mutant pCMVAR 1–660 (10 ng/
dish) that lacks the ligand binding domain with MMTV-Luc and PSA-
Luc (0.5 and 1 g/dish) or 10 ng of empty parent vector pCMV5 (C).
Cells were incubated for 24 h in the absence and presence of 10, 100,
and 500 ng/ml EGF with and without 0.1 nM DHT as indicated. The
mean luciferase activity values in optical units plus error of the mean
are representative of at least three independent experiments.
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suggest that an effect of EGF on AR stabilization could not be
detected in COS cells.
Role of MAPK—We determined whether the EGF-induced
increase in AR transcriptional activity was associated with an
increase in MAPK activity. Growth factor activation of MAPK
results in phosphorylation at threonine 202 and tyrosine 204 in
ERK1 (pp42) and ERK2 (pp44) that can be detected on immu-
noblots using phosphorylation-specific antibodies (77). Within
15 min of treating CWR-R1, COS, and CV1 cells with 100 ng/ml
EGF, specific phosphorylation of ERK1 (pp42) and ERK2
(pp44) was detected, followed by a decline in signal intensity
over 24 h in the three cell lines (Fig. 3). The rapid increase in
MAPK activity in CWR-R1 cells in response to EGF was inhib-
ited by pretreatment with 10 M U0126, a MEK1 and MEK2
inhibitor that prevents phosphorylation of ERK1/2 (data not
shown).
The effects of the MEK inhibitor U0126 and the EGF recep-
tor (ErbB1)-specific inhibitor ZD1839 were tested on endoge-
nous AR transactivation in CWR-R1 cells in the absence and
presence of EGF using the MMTV-Luc reporter (Fig. 4A). In-
creasing concentrations of U0126 from 0.1 to 2.5 M inhibited
AR transactivation in the absence and presence of added EGF.
In contrast, ZD1839 blocked the EGF-induced increase in lu-
ciferase activity but had no effect on the transcriptional re-
sponse in the absence of added EGF. Control experiments
indicated that U0126 and ZD1839 did not inhibit general tran-
scription, since the same concentrations of inhibitors in
CWR-R1 cells did not reduce the activity of constitutively ac-
tive reporter vectors pSG5-Luc, pSV2-Luc, or pA3RSV400Luc
(78) (data not shown).
The data indicate that the transcriptional capacity of the
androgen-activated endogenous AR in CWR-R1 cells is in-
creased by EGF through the MAPK pathway. The kinase in-
hibitor results suggest that a possible autocrine regulatory loop
involving ligands in the EGF family is present in CWR-R1 cells
and may not depend solely on the ErbB1 receptor, since the
EGF receptor-selective inhibitor ZD1839 did not diminish AR
activity in the absence of added EGF. On the other hand,
inhibition of transcription by U0126 in the absence of added
EGF suggested that other members of the EGF receptor family,
such as ErbB2 and ErbB3, mediate signals through the MAPK
pathway to increase DHT-dependent AR transcriptional activ-
ity in the CWR-R1 recurrent prostate cancer cell line.
The MAPK pathway was also implicated in the EGF-induced
increase in AR observed in COS cells in the presence of DHT.
ZD1839 (2.5 M) and U0126 (2.5 M) blocked the EGF-induced
increase in AR levels observed in the presence of DHT (Fig. 4B).
In contrast, these inhibitors had no effect on DHT-induced AR
stabilization (Fig. 4B) that was shown previously to require the
androgen-induced NH2-terminal and carboxyl-terminal (N/C)
interaction in AR (79). The results support that MAPK signal-
ing acts synergistically with DHT.
EGF Regulation of TIF2 Expression—We showed previously
that progression to recurrent growth of prostate cancer is as-
sociated with increased levels of p160 coactivators (44) that can
increase AR activity (68). We therefore investigated expression
levels and effects of EGF on endogenous TIF2 levels in several
cell lines including the CWR-R1 cell line and in the CWR22
human prostate cancer xenograft. Steady state levels of TIF2
were highest in the CWR-R1 cell line compared with prostate
cancer cell lines PC3, LNCaP, and LNCaP-C4-2 and HeLa cells
when equal amounts of protein were analyzed by immunoblot
(Fig. 5A). Lower levels of TIF2 were detected in COS and CV1
cells, and TIF2 was undetectable in a nontransformed human
foreskin fibroblast cell line. EGF increased TIF2 levels in
CWR-R1 cells after 8 h compared with an earlier increase in
COS cells and little change in CV1 cells (Fig. 5B). The higher
steady state level of TIF2 in CWR-R1 cells and the increase
after EGF treatment support the possibility that elevated lev-
els of TIF2 contribute to the EGF-induced increase in androgen-
dependent AR transactivation. We ruled out a direct effect of
EGF on TIF2 transcription, since Northern blot analysis
showed similar levels of TIF2 mRNA in CWR-R1 cells with and
without EGF treatment (Fig. 5C).
FIG. 3. EGF-induced MAPK activity. CV1, COS, and CWR-R1 cells
were incubated with 100 ng/ml EGF for the times indicated from 15 min
to 24 h. Immunoblots of cell lysates (50 g of protein/lane) were incu-
bated with phospho-p42/p44 antibody as described under “Experimen-
tal Procedures.” The data are representative of at least three independ-
ent experiments.
FIG. 4. Inhibition of AR transactivation and EGF-induced AR
stabilization by EGF receptor and MEK inhibitors. In A, trans-
activation by endogenous AR was determined in CWR-R1 cells trans-
fected with MMTV-Luc (0.5 g/6-cm dish) as described under “Experi-
mental Procedures.” Cells were incubated for 24 h with and without 0.1
nM DHT in the absence and presence of 100 ng/ml EGF and increasing
concentrations (0.1–2.5 M) of the MEK inhibitor U0126 or the EGF
receptor (ErbB1) inhibitor ZD1839. Luciferase activity is shown as the
mean and error and is representative of at least three experiments. In
B, pCMV5 empty parent vector (lane 1) and pCMVhAR (2 g of DNA/
10-cm dish; lanes 2–6) were transiently expressed in COS cells. Cells
were treated in the absence and presence of 10 nM DHT with or without
100 ng/ml EGF as indicated. Some of the cells treated with DHT and
EGF were also incubated with 2.5 M ZD1839 (lane 5) or 2.5 M U0126
(lane 6). Immunoblots of cell lysates (25 g of protein/lane) were probed
with the AR32 antibody. Densitometry values for specific bands are
included above the lanes.
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The EGF-induced increase in TIF2 levels was also observed
in the androgen-dependent CWR22 tumor that was propagated
in nu/nu athymic mice implanted with testosterone pellets (62,
72) (Fig. 5D). Six days after castration and removal of the
testosterone source, TIF2 was barely detectable in the CWR22
androgen-dependent tumor (Fig. 5D, lanes 1–3) but increased
4–6-fold when mice were treated 6 days after castration with
EGF and analyzed 48 h later (lane 5). TIF2 levels also in-
creased 5–10-fold after mice were treated with a single injec-
tion of 25 mg/kg testosterone propionate 6 days after castration
and analyzed 72 h later (lane 4). The increase in TIF2 levels in
response to testosterone could be indirect through EGF, since
testosterone has been shown to increase circulating EGF levels
in castrated mice (80, 81). Testosterone may also increase EGF
levels through a direct effect on xenograft tumor cells. In the
recurrent CWR22 tumor that develops after prolonged andro-
gen deprivation, TIF2 levels were elevated in the absence of
androgen replacement (Fig. 5D), suggesting that additionalFIG. 5. Endogenous TIF2 expression and regulation by EGF. In
A, endogenous TIF2 levels were assessed in whole cell lysates from the
indicated cell lines harvested during logarithmic growth. The immuno-
blot was performed on cell extracts (50 g of protein/lane) prepared in
RIPA buffer in the presence of protease inhibitors. All cell lines were
grown in the absence of supplemental EGF. Blots were probed with
anti-TIF2 antibody (BD Biosciences). In B, CV1, COS, and CWR-R1
cells were untreated (0) or were incubated with 100 ng/ml EGF for
increasing times from 15 min to 24 h as indicated. The blot was probed
with the anti-TIF2 antibody. For the Northern blot in C, CWR-R1 cells
were incubated without and with EGF (100 ng/ml) in the absence of
serum for 24 h. RNA was isolated using TRIzol reagent as described
under “Experimental Procedures.” 15 g of RNA was fractionated on 1%
agarose gels, transferred to a nylon membrane, and hybridized with
32P-labeled TIF2 and 18 S ribosomal RNA cDNAs. Densitometry values
of the specific bands are included below the lanes. In D, the levels of AR
(upper panel) and TIF2 (lower panel) were determined by immunoblot of
FIG. 6. Effects of EGF on TIF2 phosphorylation and interac-
tion with AR by TIF2 immunoprecipitation. CWR-R1 cells were
incubated with and without 100 ng/ml EGF in the absence of serum for
24 h. Equal amounts of protein (4 mg) from cell lysates were immuno-
precipitated (IP) using anti-TIF2 monoclonal antibody as described
under “Experimental Procedures.” In A, immunoprecipitated TIF2 was
subjected to immunoblot analysis using anti-TIF2 antibody. In B,
CWR-R1 cells were incubated with 1 nM DHT in the absence and
presence of 100 ng/ml EGF, and equal amounts of cell lysate protein
were immunoprecipitated with anti-TIF2 antibody. Shown is an immu-
noblot using anti-phosphoserine antibodies (pSer) to detect phosphoryl-
ated TIF2. In C, CWR-R1 cells were incubated with 1 nM DHT with and
without 100 ng/ml EGF, and equal amounts of cell lysate protein were
immunoprecipitated using anti-TIF2 antibodies. The immunoblot was
probed with AR polyclonal antibody AR32 to detect AR co-immunopre-
cipitated with TIF2. The data are representative of at least three
independent experiments.
cell lysates from the androgen-dependent CWR22 tumor (lane 1), and
from CWR22 tumors harvested 1 day (lane 2), 6 days (lanes 3–5), and
120 days (lane 6) after castration and removal of the testosterone
implants. The recurrent tumors were propagated in castrated mice and
harvested 45 days later (lane 7). Six days after castration, some mice
received a single injection of 25 mg/kg testosterone propionate in ses-
ame oil intraperitoneally, and cell lysates were prepared 72 h later (lane
4), or mice received a single injection of 150 g/kg subcutaneous EGF in
sterile water, and cell lysates were prepared 48 h later (lane 5). Immu-
noblots of cell lysates (100 g of protein/lane) were incubated with AR32
or TIF2 antibody. Data in A represent two independent experiments,
data in B represent three experiments, and data in C represent 2–6
tumors in each treatment group.
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mechanisms such as autocrine signaling contribute to in-
creased TIF2 levels in prostate cancer tumor progression.
AR levels also increased after testosterone treatment 6 days
after castration and to a lesser extent with EGF alone (Fig. 5D).
In comparison with the tumor analyzed 6 days after castration,
the recurring CWR22 tumor growing at 120 days after castra-
tion showed higher AR expression that approached the level
observed in the recurrent tumor as reported previously (82).
The results indicate that androgen and EGF increase TIF2 and
AR levels in the androgen-sensitive CWR22 tumor to levels
seen in the recurrent tumor.
Mechanism for the EGF-induced Increase in AR Transacti-
vation—The EGF-induced increase in TIF2 levels and AR
transactivation led us to investigate TIF2 phosphorylation,
since previous studies on the estrogen and progesterone recep-
tors suggested that EGF increases phosphorylation of p160
coactivators (83). Using an anti-TIF2-specific antibody, TIF2
was immunoprecipitated from lysates of CWR-R1 cells incu-
bated in the absence and presence of EGF (Fig. 6A). Immuno-
blotting using phosphoserine antibodies suggested an increase
in TIF2 phosphorylation in the presence of EGF (Fig. 6B).
Moreover, in a separate experiment in the presence of DHT, we
found that AR coimmunoprecipitated with TIF2, and the
amount of AR in the coimmunoprecipitate increased in the
presence of EGF (Fig. 6C). The data raised the possibility that
EGF-induced phosphorylation of TIF2 increases its interaction
with AR.
The proximity of the TIF2 MAPK site Ser736 and the third
LXXLL motif of TIF2 (Fig. 7A) suggested that EGF-induced
phosphorylation of TIF2 might increase AR transactivation by
enhancing its interaction with AR. The third LXXLL motif of
TIF2 is the predominant interaction site among the three
LXXLL motifs that bind activation function 2 (AF2) in the AR
ligand binding domain (68, 78). Coexpression of GRIP1, the
mouse homologue of human TIF2 that differs by only 2 amino
acids (83), with an MMTV-Luc reporter increased DHT-de-
pendent transcriptional activity of endogenous AR in CWR-R1
cells in the absence and presence of EGF (Fig. 7B). When the
GRIP1-S736A phosphorylation mutant was expressed, the
transcriptional response to DHT alone and to DHT and EGF
was similar to that observed in the absence of GRIP1 transient
expression. Transient expression levels of GRIP1 and the
GRIP1-S736A mutant were similar, as shown in immunoblots
of COS cell extracts (Fig. 7C, lanes 3 and 6), in agreement with
a previous report (83), suggesting that expression levels were
also similar in CWR-R1 cells. A direct comparison of expression
levels of the wild-type and mutant GRIP1 plasmids in CWR-R1
cells was complicated by the relatively high TIF2 levels in
CWR-R1 cells (see Fig. 5A) combined with low expression of
plasmid DNA. As shown above (Fig. 5B), EGF increased endog-
enous TIF2/GRIP1 levels in COS cells (Fig. 7C, lanes 1 and 2)
and the levels of transiently expressed GRIP1 but not the
GRIP1-S736A mutant (Fig. 7C, lanes 5 and 6). The data sug-
FIG. 7. Effects of EGF on the AR-TIF2/GRIP1 interaction. A,
schematic diagram of the three LXXLL motifs of TIF2/GRIP1 and their
position relative to the MAPK consensus site at Ser736 that flanks the
third LXXLL motif of TIF2/GRIP1, the predominant interaction site for
the AR AF2 region (67, 70). Amino acid residues are numbered. B,
CWR-R1 cells were transfected with MMTV-Luc (0.5 g/6-cm dish) and
0.1 g/dish of pSG5 empty vector, pSG5-GRIP1, or pSG5-GRIP1-S736A.
Cells were incubated for 24 h in the absence and presence of 0.1 nM DHT
with and without 100 ng/ml EGF as indicated. In C, immunoblot of
endogenous TIF2 (lanes 1 and 2), transiently transfected pSG5-GRIP1
(lanes 3 and 4), and pSG5-GRIP1-S736A (lanes 5 and 6) before and after
treatment with 100 ng/ml EGF for 24 h. 50 g of protein extracts of COS
cells were analyzed by immunoblot using the TIF2 antibody as de-
scribed under “Experimental Procedures.” Exposure times of the film
were 5 min to detect endogenous TIF2 (lanes 1 and 2) and 30 s for
transiently expressed TIF2/GRIP1 (lanes 3–6).
FIG. 8. Effect of EGF on the interaction between AR and TIF2.
In A, two hybrid interaction assays were performed in CWR-R1 cells by
cotransfecting 10 ng of VPTIF2.1 (TIF2 residues 624–1287) or VP-
TIF2.1-S736A with 100 ng of GAL-AR 624–919 and 0.1 g of
5GAL4Luc3. CWR-R1 cells were incubated with or without 1 nM DHT
in the absence and presence of 100 ng/ml EGF. The mean and S.E. of
luciferase activity are representative of three independent experiments.
In B, COS cells were transiently transfected as described under “Ex-
perimental Procedures” with 1 g each of VP-TIF2.1 or VPTIF2.1-
S736A with and without 1 g of GAL-AR 624–919 using Effectene
reagent. Cells were incubated overnight in the absence and presence of
EGF (100 ng/ml) with and without 10 nM DHT. Cell lysates (10 g of
protein/lane) were immunoblotted, and membranes were incubated
with anti-TIF2 antibody. The data are representative of three inde-
pendent experiments.
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gest that the EGF-induced increase in AR transcriptional ac-
tivity is mediated at least in part by phosphorylation of GRIP1
at Ser736 and by increased levels of TIF2/GRIP1.
The requirement for GRIP1 phosphorylation in its interac-
tion with AR was evaluated further in the CWR-R1 cell line
using a two-hybrid interaction assay. VPTIF2.1 coding for the
VP16 activation domain and TIF2 residues 624–1287 (39, 70)
was co-expressed with GAL-AR 624–919 coding for the AR
ligand binding domain and GAL4 DNA binding domain. The
androgen-dependent interaction between GAL-AR 624–919
and VPTIF2.1 was reduced with the phosphorylation site mu-
tant VPTIF2.1-S736A (Fig. 8A). The addition of EGF increased
the interaction between AR and VPTIF2.1 and between AR and
VPTIF2.1-S736A but was greater for wild-type TIF2. The high
levels of endogenous TIF2 in CWR-R1 cells probably contrib-
uted to some of the activity observed in the presence of the TIF2
mutant. Expression levels of the VPTIF2.1 and VPTIF2.1-
S736A plasmid DNA were similar in the absence and presence
of GAL-AR 624–919, as demonstrated in COS cells (Fig. 8B).
The results suggest that EGF increases the interaction be-
tween AR and TIF2 through phosphorylation at serine 736
adjacent to the third LXXLL motif and probably through addi-
tional phosphorylation sites in TIF2.
Role of the AR N/C Interaction—We showed previously that
the androgen-dependent AR NH2- and carboxyl-terminal N/C
interaction is mediated by the NH2-terminal FXXLF and
WXXLF motifs (66) and is required for DHT-induced AR sta-
bilization (67, 84) and slows the dissociation rate of bound
androgen (66, 67, 79). The AR-FXXAA/AXXAA mutant that
lacks the N/C interaction activates the MMTV-Luc reporter in
CV1 cells to essentially the same extent as wild-type AR, but in
CV1 cells this mutant only weakly activates the PSA-Luc re-
porter compared with wild-type AR (68). We now show that
transiently expressed AR-FXXAA/AXXAA in CWR-R1 cells is
equipotent to wild-type AR in activating PSA-Luc (Fig. 9), and
EGF increases the androgen-dependent activity.
Previous studies demonstrated that increased expression of
TIF2 in CV1 cells could overcome the requirement for the AR
N/C interaction in activating the PSA-Luc reporter (68). Since
an important functional consequence of the N/C interaction is
stabilization of the AR that may be necessary for AR activity in
vivo (67, 79, 84), we investigated whether increased coactivator
levels could replace this function by stabilizing the AR-FXXAA/
AXXAA mutant. Under conditions of low endogenous TIF2/
GRIP1 levels in COS cells, DHT had little effect on AR-FXXAA/
AXXAA levels compared with the increase seen with wild-type
AR (Fig. 10), as previously reported (67). The addition of EGF
only slightly increased AR-FXXAA/AXXAA levels in the pres-
ence or absence of DHT. In contrast, when GRIP1 was overex-
pressed, there was a striking increase in AR-FXXAA/AXXAA
levels with DHT, which was further increased in the presence
of EGF (Fig. 10). It is noteworthy that EGF in the presence of
GRIP1 but in the absence of androgen also increased AR-
FXXAA/AXXAA levels. The results suggest that increased
TIF2/GRIP1 expression that can occur in response to EGF and
that is frequently observed in recurrent prostate cancer (44)
contributes to increased AR-mediated transactivation. In-
creased levels of TIF2 may compete more effectively for the N/C
interaction, resulting in increased coactivator recruitment and
AR transactivation.
Effect of TIF2/GRIP1 siRNA on AR Transactivation—To
determine whether TIF2/GRIP1 is required for AR transacti-
vation by DHT and EGF in CWR-R1 cells, we used RNA inter-
ference to inhibit endogenous TIF2/GRIP1 expression. An
siRNA mixture consisting of 12–30 bp of double-stranded RNA
coding for TIF2/GRIP1 was transiently transfected into
CWR-R1 cells together with pCMVhAR and PSA-Luc. TIF2
siRNA directed at nucleotides 197–376 inhibited AR transac-
tivation of PSA-Luc by 5-fold, whereas a glyceraldehyde-3-
phosphate dehydrogenase siRNA mixture had no effect (Fig.
11). Specificity for the TIF2 siRNA inhibition was established
by cotransfecting pSG5TIF2 with 10 nM TIF2 siRNA. Partial
recovery of AR transactivation of PSA-Luc activity in the pres-
ence of overexpressed TIF2 provided evidence that inhibition
by TIF2 siRNA was specific.
FIG. 9. Transcriptional activation of PSA-Luc by an AR N/C
interaction mutant in CWR-R1 cells. CWR-R1 cells were trans-
fected with 1 g of PSA-Luc reporter and 10 ng of pCMVhAR or the AR
N/C interaction mutant pCMVhAR-FXXAA/AXXAA in which
23FQNLF27 and 433WHTLF437 in the AR NH2-terminal domain were
mutated to FQNAA and AHTAA, respectively (66). Cells were trans-
fected using Effectene as described under “Experimental Procedures”
and incubated for 24 h with and without increasing concentrations of
DHT as indicated in the absence and presence of 100 ng/ml EGF. The
data are representative of three independent experiments.
FIG. 10. Effects of EGF and GRIP1 on expression levels of AR
and the AR N/C interaction mutant. Wild-type and N/C interaction
mutant AR levels were determined in COS cells by transient expression
of 1 g of wild-type pCMVhAR or pCMVhAR-FXXAA/AXXAA in the
absence and presence of 1 g of pSG5 empty vector or pSG5-GRIP1
using Effectene as described under “Experimental Procedures.” Cells
were treated in the absence and presence of 10 nM DHT with and
without 100 ng/ml EGF as indicated. Immunoblots were probed with
AR antibody AR32 from cell lysates (25 g of protein/lane) for wild-type
AR and the N/C interaction mutant AR-FXXAA/AXXAA in the absence
(A) or presence (B) of transiently expressed GRIP1. Densitometry val-
ues for specific bands are included below the lanes.
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DISCUSSION
The recurrent growth of prostate cancer after prolonged an-
drogen deprivation is recapitulated by human xenograft mod-
els such as CWR22 (22, 62, 85) and LAPC-4 and LAPC-9 (86)
prostatetumors.Likehumanprostatecancersthatareandrogen-
dependent for growth, these human tumors propagated in nude
mice regress following androgen withdrawal by castration but
after several months regrow in an environment of low circulat-
ing androgen. Most reports implicate a critical role for the AR
in recurrent prostate cancer growth and progression despite
reduced circulating androgen levels, and some studies suggest
that mitogen signaling bypasses the requirement for androgen.
In the present report, we provide evidence that EGF signaling
through MAPK increases androgen-dependent AR transcrip-
tional activity in the CWR-R1 recurrent human prostate cancer
cell line. EGF increased androgen-dependent AR transactiva-
tion in association with increased levels of TIF2 in the CWR-R1
cell line. EGF and testosterone each increased AR and TIF2
levels in the androgen-dependent CWR22 xenograft tumor,
supporting their complementary relationship. EGF increased
TIF2 phosphorylation and the interaction between phosphoryl-
ated forms of TIF2 and AR. The effects of EGF were mediated
in part through phosphorylation of TIF2/GRIP1 at Ser736.
TIF2/GRIP1 in CWR-R1 cells also probably contributed to in-
creased transactivation by the NH2-terminal activation func-
tion 1 of the AR NH2-terminal DNA binding domain fragment
AR 1–660. Reducing TIF2/GRIP1 levels in CWR-R1 cells using
inhibitory RNAs resulted in a decreased AR transcriptional
response to DHT and EGF. The data provide evidence for a
direct link between AR transcriptional activity in recurrent
prostate cancer, EGF signaling, and increased p160 coactivator
levels. In addition, the studies provide a mechanism to explain
the recent finding that a majority of recurrent prostate cancers
have elevated levels of TIF2 (44).
Mechanisms described thus far to account for increased AR
transactivation in recurrent prostate cancer include ligand-
independent activation by mitogen signaling, AR overexpres-
sion, and AR mutations. Of these, increased signaling by EGF
and TGF was reported to occur in association with the tran-
sition from androgen-dependent to recurrent prostate cancer
(87), and prostate cancer cell lines have been shown to synthe-
size and secrete EGF and related peptides (88). In addition, the
EGF family of receptors is expressed in most recurrent prostate
cancers (89), with ErbB2 protein expression most frequently
reported (90–93). The CWR22 xenograft (62, 94–97) expresses
ErbB1, -2, and -3 as shown by reverse transcription PCR (62,
94, 95), and the CWR-R1 cell line expresses ErbB1, -2, -3, and
-4.2 This agrees with reports that the ErbB1 inhibitor ZD1839
reduces the growth of androgen-dependent and recurrent
CWR22 cells in culture (98) and that growth in primary cul-
tures of androgen-dependent and recurrent CWR22 cells was
inhibited by a monoclonal antibody to ErbB2 that blocked
heregulin-induced activation of MAPK and Akt (94).
The link between EGF signaling and AR is supported by a
number of previous studies, most of which relied on the over-
expression of key signaling molecules. In the LNCaP prostate
cancer cell line, increased growth and PSA expression were
observed after stable overexpression of ErbB2 through the
MAPK pathway (99). Overexpression of ErbB2 was associated
with ligand-independent activation of AR in recurrent prostate
cancer growth (99). Cell signaling by interleukin-6 in LNCaP
cells was mediated by tyrosine phosphorylation of ErbB2 and
ErbB3 (100). Stable overexpression of a constitutively active
mitogen-activated protein kinase kinase kinase 1-induced apo-
ptosis in LNCaP cells expressing AR, but there was no change
in PC3 or DU145 cells that lack AR expression (101). ErbB2
was reported to activate Akt-directed phosphorylation at AR
serine residues 213 and 791 in association with growth of
recurrent prostate cancer in the absence of androgen (102).
MAPK-directed AR phosphorylation was also implicated in
hormone-independent AR activation in prostate cancer (99,
101). Overall, the results support the link between the MAPK
pathway and AR transcriptional activity.
The data presented in this report indicate that increased AR
transcriptional activity occurs in response to EGF in part from
an increase in the androgen-dependent association between AR
and TIF2/GRIP1. The interaction between p160 coactivator
TIF2/GRIP1 and AR is mediated primarily by binding of the
third LXXLL motif of TIF2 to the AF2 hydrophobic surface in
the AR ligand binding domain (103–105). Under normal condi-
tions of low coactivator expression as shown here for a human
foreskin fibroblast cell line, AR interaction with p160 coactiva-
tors might be limited by the lower binding affinity of the coac-
tivator LXXLL motifs to the AR AF2 binding site compared
with binding of the AR NH2-terminal FXXLF motif that medi-
ates the androgen-dependent N/C interaction (66, 106). An
optimal transcriptional response of AR to TIF2/GRIP1 depends
on the interaction between the LXXLL motifs and the AR AF2
region (68). We have shown previously that increased levels of
p160 coactivators compete for the androgen-induced N/C inter-
action to gain access to the AF2 region in the ligand binding
domain (67). Mutating Ser736 adjacent to the third and predom-
inant interacting LXXLL motif of TIF2/GRIP1 reduced the
interaction between TIF2/GRIP1 and AR, supporting a key role
for LXXLL motif binding. The importance of phosphorylation at
TIF2/GRIP1 serine 736 was shown previously for coactivation
of the estrogen and progesterone receptors (83). In the present
report, we provide further evidence that this MAPK signaling
pathway contributes to increased AR transactivation in recur-
rent prostate cancer.
We found that transient expression of TIF2/GRIP1 in the
presence of DHT and EGF had a stabilizing effect on AR-
FXXAA/AXXAA, an AR with mutations in the NH2-terminal
23FQNLF27 and 433WHTLF437 sequences that are required for
the androgen-induced AR N/C interaction (66–68). Mutations
2 C. W. Gregory, W. McCall, X. Fei, Y. E. Whang, F. S. French, E. M.
Wilson, and H. S. Earys, unpublished results.
FIG. 11. Interference of AR transcriptional activity by TIF2
siRNA. CWR-R1 cells were transfected with the PSA-Luc reporter and
pCMVhAR with and without 10 nM glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) siRNA or TIF2 siRNA in the absence and presence
of 0.05 g of pSG5 or pSG5-TIF2 using Effectene as described under
“Experimental Procedures.” Cells were incubated for 24 h with and
without 0.1 nM DHT in the absence and presence of 100 ng/ml EGF. The
data are representative of four independent experiments.
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that cause loss of the N/C interaction allow greater accessibility
of AF2 in the ligand binding domain to activation by p160
coactivators such as TIF2/GRIP1 (67). Surprisingly, whereas
loss of the N/C interaction reduced AR transactivation of the
PSA promoter in other cell lines (68), this mutant was as
effective as wild-type AR when assayed in the CWR-R1 cell
line, supporting the notion that higher levels of TIF2 compen-
sate for loss of the AR N/C interaction.
EGF also increased transactivation by the AR NH2-terminal
and DNA binding domain fragment AR 1–660 that lacks the
ligand binding domain. This agrees with previous reports that
p160 coactivators interact with multiple regions of steroid re-
ceptors, including an interaction between the glutamine-rich
region of p160 coactivators and the NH2-terminal domains of
steroid receptors (70, 107, 108). The EGF-induced increased in
TIF2/GRIP1 activity in CWR-R1 cells therefore also probably
contributes to AR transactivation through interactions with
the AR NH2-terminal region. Previous studies on the effects of
EGF on the progesterone and estrogen receptors support in-
creased p160 coactivator activity as a mechanism for growth
factor regulation of nuclear receptors (83).
Evidence presented here and previously suggests that recur-
rent prostate cancer is influenced by autocrine loops involving
EGF signaling. Recurrent growth of the androgen-dependent
CWR22 xenograft in the absence of testis-derived androgen
occurred in the presence of increased expression of TGF,
which could establish an autocrine regulatory loop through the
EGF receptor (87). Recurrent CWR22 tumors express high
levels of EGF-related ligands compared with the androgen-de-
pendent tumor (94), and increased immunostaining of TGF
was found in recurrent CWR22 xenografts (87). Further sup-
port for an autocrine regulatory loop comes from observations
that CWR-R1 cells express EGF, heparin-binding EGF, TGF,
and heregulin messenger RNAs.2 In the present report, we
show that ZD1839, an EGF receptor (ErbB1)-specific inhibitor,
did not diminish the transcriptional activity of endogenous AR
in CWR-R1 cells, whereas the downstream MEK inhibitor
U0126 decreased DHT-induced AR transactivation in CWR-R1
cells in the absence of added EGF. These data suggest that an
endogenous EGF or TGF-like ligand induces MAPK signaling
independent of the EGF receptor, ErbB1. The ErbB2 and
ErbB3 receptors may therefore be key modulators of AR acti-
vation in CWR-R1 cells, as reported for heregulin and ErbB3 in
advanced prostate cancer (61). EGF-related peptides produced
by CWR-R1 cells could interact with other members of the EGF
receptor family (50). Our studies did not provide evidence that
autocrine signaling through the EGF receptor family can over-
ride a requirement for androgen. Rather, autocrine regulation
of recurrent prostate cancer cells appears to contribute to an-
drogen-activated AR-mediated gene transcription. Earlier evi-
dence suggested that prostate cancer cells establish an auto-
crine loop through EGF or TGF and their receptors (109), and
studies cited above indicate that this autocrine loop is present
in the recurrent CWR22 xenograft and CWR-R1 cell line.
The apparent requirement for androgen by recurrent pros-
tate cancer cells for AR transactivation raises the question of
the source of ligand. In prostate cancer patients that are cas-
trated or treated with luteinizing hormone-releasing hormone
agonists to suppress testicular androgen production in re-
sponse to pituitary luteinizing hormone, adrenal androgens
circulate at levels sufficient to serve as precursors for the
biosynthesis of testosterone and DHT. Remarkably, testoster-
one levels in recurrent prostate cancer tissue specimens during
androgen withdrawal therapy were found to be similar to levels
in benign prostate hyperplasia tissue from untreated patients
(110). DHT levels in recurrent prostate cancer tissue were
reduced to 10% compared with benign prostate. These results
suggest that tissue androgen production may be sufficient in
recurrent prostate cancer to activate AR after the withdrawal
of circulating androgen. Furthermore, the range of steroids
that activate AR in some prostate cancers is increased by
certain AR mutations in the ligand binding domain, such as the
LNCaP AR mutant T877A and AR-H874Y mutant in the
CWR22 tumor and derived cell lines (31). Human prostate
cancer xenografts expressing wild-type AR (10, 86) have a
pattern of recurrent growth in nu/nu mice like that for recur-
rent prostate cancer in patients after androgen deprivation by
castration, suggesting that tissue androgen or other AR-acti-
vating ligands are sufficient in the xenografts to trigger AR
transactivation.
Therapeutic strategies for prostate cancer have been aimed
recently at inhibiting the EGF signaling pathway. Inhibitors
such as GW572016 gained attention in attempts to block tumor
progression (111). This approach was effective in targeting
ErbB2 for the treatment of breast cancer. But unlike breast
cancer, where ErbB2 receptors are frequently overexpressed
(112), these receptors are present but not highly expressed in
most recurrent prostate cancer specimens (90, 99). Clinical tar-
geting of ErbB2 with antitumor agents such as Herceptin (tras-
tuzumab), a humanized monoclonal antibody to the extracellular
domain of ErbB2, was ineffective in advanced prostate cancer
patients that were negative for ErbB2 expression (113) but more
effective when receptors were overexpressed (114). The anti-
ErbB2 antibody Herceptin inhibited growth of androgen-depend-
ent CWR22 and LNCaP xenografts but did not inhibit growth of
the recurrent CWR22 tumor (115). A monoclonal antibody that
binds a different region from the Herceptin binding site inhibited
association of ErbB2 receptor with other EGF receptor family
members, blocking heregulin-mediated signaling in androgen-
dependent and -independent prostate cancer cell lines (94). Other
approaches have been taken to inhibit prostate tumor growth by
indirectly targeting the AR. Proliferation of prostate cancer cells
and xenografts was reduced by an hsp90 inhibitor and decreased
AR, ErbB2, and Akt expression levels, supporting the role of
these pathways in androgen-dependent and recurrent tumor
growth (116).
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